89bio Removed from S&P Global BMI Index Amid NASH Treatment Development
ByAinvest
Wednesday, Oct 29, 2025 9:08 pm ET1min read
ETNB--
89bio, Inc. has been removed from the S&P Global BMI Index. The company is a clinical-stage biopharmaceutical firm focused on developing treatments for liver and cardio-metabolic diseases. Its lead product candidate, pegozafermin, is being developed for NASH and SHTG. Pegozafermin is a glycoPEGylated analog of FGF21 designed to protect against proteolysis and reduce renal clearance. The company conducted a Phase I clinical trial to evaluate its safety, tolerability, and pharmacokinetics.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet